Cann has established research and development and cultivation facilities in Australia and has executed collaboration agreements that will enable it to establish a leading position in plant genetics; breeding; cultivation; extraction; analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
On 17 February 2017, Cann was issued Australia’s first Medicinal Cannabis Research Licence issued in accordance with the Narcotic Drugs Act 1967. This Licence will enable Cann to cultivate medicinal cannabis and conduct research on the use of cannabis for medicinal purposes, including the formulation of medicinal cannabinoid oil, of consistent quality, for a range of patient conditions that may benefit from medicinal cannabis.
In addition to the cannabis research licence the company, on 8 March 2017 Cann was issued Australia’s first Medicinal Cannabis Cultivation Licence. The new licence allows Cann Group to produce Australian grown material that can be prescribed for patient use
Cann’s vision is to be a leading developer and supplier of cannabis, cannabis resin and medicinal cannabis products.